The micro invasive glaucoma surgery (MIGS) devices market offers a range of product types, including MIGS shunt, MIGS stent, trabectome, kahook dual blade, tube shunt, micro-implants, micro catheters, and more. These innovative devices provide minimally invasive solutions for glaucoma management. They target patients seeking effective, low-risk treatment options, particularly those with mild to moderate glaucoma. The market presents opportunities for companies to meet the growing demand for advanced, less invasive glaucoma treatments, offering improved patient outcomes and quality of life.
Access Full Report @ https://www.databridgemarketresearch.com/ar/reports/europe-micro-invasive-glaucoma-surgery-migs-devices-market
Data Bridge Market Research analyses that the Europe Micro Invasive Glaucoma Surgery (MIGS) Devices Market was valued at USD 217.05 million in 2022 and is expected to reach the value of USD 1,738.15 million by 2030, at a CAGR of 29.7% during the forecast period 2023-2030. The increasing prevalence of glaucoma and related eye conditions is a primary driver for the micro invasive glaucoma surgery (MIGS) devices market. This rising demand underscores the need for advanced and efficient treatment options offering better outcomes and reduced patient risks.
Key Findings of the Study
Aging population is expected to drive the market's growth rate
As the global population ages, the prevalence of glaucoma rises, contributing significantly to the growth of the micro invasive glaucoma surgery (MIGS) devices market. With aging being a primary risk factor for glaucoma, there is a growing demand for advanced, minimally invasive treatment options that cater to an older demographic. MIGS devices address this need, providing a safer and more effective approach for managing glaucoma in older patients, thereby driving market expansion.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (MIGS Shunt, MIGS Stent, Trabectome, Kahook Dual Blade, Tube Shunt, Micro-Implants, Micro Catheters and Others), Target (Trabecular Meshwork, Suprachoroidal Space, Subconjunctival Filtration, Reducing Aqueous Production and Others), Surgery Type (Glaucoma in Conjunction with Cataract, Stand-Alone Glaucoma), Glaucoma Type (Open Angle Glaucoma, Acute Angle-Closure Glaucoma, Normal-Tension Glaucoma, Secondary Glaucoma, Pigmentary Glaucoma and Congenital Glaucoma), End User (Hospital's Outpatients Department (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Glaukos Corporation (U.S.), AbbVie Inc. (U.S.), Alcon (Switzerland), Johnson & Johnson Vision Care Inc. (U.S.), Sight Sciences, Inc. (U.S.), Santen Pharmaceutical Co., Ltd (Japan), iSTAR Medical (Belgium), BVI (U.S.), Nova Eye Medical (Australia), Lumenis Ltd (Israel), Inami & Co., Ltd (Japan), Oertli Instrumente AG (Switzerland), Lumibird (France)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe micro invasive glaucoma surgery (MIGS) devices market is categorized into six segments by product type, target, surgery type, glaucoma type, end user, and distribution channel.
- On the basis of product type, the Europe micro invasive glaucoma surgery (MIGS) devices market is segmented into MIGS shunts, MIGS stents, trabectome, kahook dual blade, tube shunt, micro implants, micro catheters, and others.
- On the basis of target, the Europe micro invasive glaucoma surgery (migs) devices market is segmented into the trabecular meshwork, suprachoroidal space, subconjunctival filtration, reducing aqueous production, and others.
- On the basis of surgery type, the Europe micro invasive glaucoma surgery (MIGS) devices market is segmented into glaucoma in conjunction with cataract and stand-alone glaucoma.
- On the basis of glaucoma type, the Europe micro invasive glaucoma surgery (migs) devices market is segmented into open angle glaucoma, acute angle closure glaucoma, normal tension glaucoma, secondary glaucoma, pigmentary glaucoma, and congenital glaucoma.
- On the basis of end user, the Europe micro invasive glaucoma surgery (MIGS) devices market is segmented into hospital outpatient departments (HOPD), ophthalmology clinics, ambulatory surgery centers (ASCS), and others.
- On the basis of distribution channel, the Europe micro invasive glaucoma surgery (MIGS) devices market is segmented into direct tender and retail sales.
Major Players
Data Bridge Market Research recognizes the following companies as the Europe micro invasive glaucoma surgery (MIGS) devices market players in Europe micro invasive glaucoma surgery (MIGS) devices market are Glaukos Corporation (U.S.), AbbVie Inc. (U.S.), Alcon (Switzerland), Johnson & Johnson Vision Care Inc. (U.S.), Sight Sciences, Inc. (U.S.), Santen Pharmaceutical Co., Ltd (Japan).
Market Developments
- In February 2022, Santen's launch of an interactive medical education platform provides ophthalmologists with high-quality, personalized learning options, enabling them to enhance their knowledge at their own pace. This initiative aims to raise awareness among healthcare professionals, particularly ophthalmologists, about Santen's products and treatment approaches. Ultimately, it fosters better patient care, contributes to the company's growth, and strengthens its position in the healthcare sector.
- In January 2022, Glaukos achieved a significant milestone by enrolling the first patient in the Phase II clinical trial for GLK-301, targeting dry eye disease. Upon successful regulatory approval, this innovative drug can potentially expand Glaukos's business segment by addressing an unmet medical need. It demonstrates the company's commitment to advancing medical solutions and paves the way for future growth opportunities in the healthcare industry.
- In January 2022, Alcon expanded its eye surgery portfolio by acquiring Ivantis, a developer of the Hydrus Microstent, a minimally invasive glaucoma surgery device. This innovative device reduces eye pressure for open-angle glaucoma patients. The acquisition signifies Alcon's commitment to offering advanced solutions. It positions the company to meet the growing demand for minimally invasive glaucoma treatments, strengthening its presence in the eye surgery segment.
Regional Analysis
Geographically, the countries covered in the Europe micro invasive glaucoma surgery (MIGS) devices market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant region in the Europe micro invasive glaucoma surgery (MIGS) devices market during the forecast period 2023-2030
Germany dominates the micro-invasive glaucoma surgery (MIGS) devices market due to a rising prevalence of glaucoma and related eye issues. MIGS devices offer minimally invasive treatment options for glaucoma patients, contributing to their growing adoption. The German healthcare system's advanced technology, skilled medical professionals, and increasing focus on eye health make it a prominent market for MIGS devices, effectively addressing the needs of a population with eye-related conditions.
For more detailed information about the Europe micro invasive glaucoma surgery (MIGS) devices market report, click here – https://www.databridgemarketresearch.com/ar/reports/europe-micro-invasive-glaucoma-surgery-migs-devices-market
